

The Gulf War era multiple sclerosis cohort: age and inc

service

Brain

135, 1778-1785

DOI: [10.1093/brain/aws099](https://doi.org/10.1093/brain/aws099)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Environmental Risk Factors for Multiple Sclerosis: A Review with a Focus on Molecular Mechanisms. International Journal of Molecular Sciences, 2012, 13, 11718-11752.	4.1	166
2	An unchanging man faced with changing times. Brain, 2012, 135, 1663-1665.	7.6	3
3	The initiation and prevention of multiple sclerosis. Nature Reviews Neurology, 2012, 8, 602-612.	10.1	253
4	Role of puberty in multiple sclerosis risk and course. Clinical Immunology, 2013, 149, 192-200.	3.2	64
5	Environmental factors in multiple sclerosis. Expert Review of Neurotherapeutics, 2013, 13, 3-9.	2.8	229
6	Incidence of Scleritis and Episcleritis: Results From the Pacific Ocular Inflammation Study. American Journal of Ophthalmology, 2013, 156, 752-758.e3.	3.3	37
7	Sexual disparities in the incidence and course of MS. Clinical Immunology, 2013, 149, 201-210.	3.2	81
9	Epidemiology in multiple sclerosis: a pilgrimâ€™s progress. Brain, 2013, 136, 2904-2917.	7.6	33
10	Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology, 2013, 80, 1734-1739.	1.1	218
11	Hospitalization Rates and Discharge Status in Multiple Sclerosis. Multiple Sclerosis International, 2013, 2013, 1-7.	0.8	18
12	Sex and gender issues in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2013, 6, 237-248.	3.5	368
13	Suicidal Behavior and Neurological Illnesses. Journal of Depression & Anxiety, 2013, 02, .	0.1	9
14	Take Home Points. , 2014, , 216-217.		1
15	Is it time for a new global classification of multiple sclerosis?. Journal of the Neurological Sciences, 2014, 344, 171-181.	0.6	66
16	Russell W Brain and the aetiology of multiple sclerosis--a historical perspective. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 423-427.	0.5	3
17	Multiple Sclerosis in Gulf War Era Veterans. 2. Military Deployment and Risk of Multiple Sclerosis in the First Gulf War. Neuroepidemiology, 2014, 42, 226-234.	2.3	13
18	Incidence of Multiple Sclerosis and Related Disorders in Asian Populations of British Columbia. Canadian Journal of Neurological Sciences, 2015, 42, 235-241.	0.5	11
19	Hormonal and gender-related immune changes in multiple sclerosis. Acta Neurologica Scandinavica, 2015, 132, 62-70.	2.1	51

#	ARTICLE	IF	CITATIONS
20	Immunogenetics of Neurological Disease. , 2015, , 39-50.		0
21	VHA Multiple Sclerosis Surveillance Registry and its similarities to other contemporary multiple sclerosis cohorts. Journal of Rehabilitation Research and Development, 2015, 52, 263-272.	1.6	16
22	Genomewide admixture study in Mexican Mestizos with multiple sclerosis. Clinical Neurology and Neurosurgery, 2015, 130, 55-60.	1.4	20
23	Genetic determinants of risk and progression in multiple sclerosis. Clinica Chimica Acta, 2015, 449, 16-22.	1.1	32
24	The immunogenetics of multiple sclerosis: A comprehensive review. Journal of Autoimmunity, 2015, 64, 13-25.	6.5	301
25	An ImmunoChip study of multiple sclerosis risk in African Americans. Brain, 2015, 138, 1518-1530.	7.6	60
26	Multiple sclerosis in US minority populations. Neurology: Clinical Practice, 2015, 5, 132-142.	1.6	94
27	Sex-Based Differences in Multiple Sclerosis (MS): Part II: Rising Incidence of Multiple Sclerosis in Women and the Vulnerability of Men to Progression of this Disease. Current Topics in Behavioral Neurosciences, 2015, 26, 57-86.	1.7	38
28	Retinal damage and vision loss in African American multiple sclerosis patients. Annals of Neurology, 2015, 77, 228-236.	5.3	53
29	EBV and Autoimmunity. Current Topics in Microbiology and Immunology, 2015, 390, 365-385.	1.1	99
30	Burden of Neurological Disease. , 2015, , 748-764.		0
31	Genetics of Multiple Sclerosis. , 2016, , 45-54.		2
32	Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Annals of Neurology, 2016, 79, 178-189.	5.3	45
33	Clinical Characteristics of Pediatric-Onset and Adult-Onset Multiple Sclerosis in Hispanic Americans. Journal of Child Neurology, 2016, 31, 1068-1073.	1.4	18
34	Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update. Seminars in Neurology, 2016, 36, 103-114.	1.4	209
35	European multiple sclerosis risk variants in the south Asian population. Multiple Sclerosis Journal, 2016, 22, 1536-1540.	3.0	15
36	The killer immunoglobulin-like receptor KIR3DL1 in combination with HLA-Bw4 is protective against multiple sclerosis in African Americans. Genes and Immunity, 2016, 17, 199-202.	4.1	29
37	Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania. Journal of Neurology, 2016, 263, 792-798.	3.6	11

#	ARTICLE	IF	CITATIONS
38	Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. <i>Journal of Medical Economics</i> , 2016, 19, 684-695.	2.1	24
39	Multiple sclerosis in men: management considerations. <i>Journal of Neurology</i> , 2016, 263, 1263-1273.	3.6	30
40	Recent research on Gulf War illness and other health problems in veterans of the 1991 Gulf War: Effects of toxicant exposures during deployment. <i>Cortex</i> , 2016, 74, 449-475.	2.4	326
41	Ethnicity and prevalence of multiple sclerosis in east London. <i>Multiple Sclerosis Journal</i> , 2017, 23, 36-42.	3.0	54
42	Adjustment modes in the trajectory of progressive multiple sclerosis: a qualitative study and conceptual model. <i>Psychology and Health</i> , 2017, 32, 343-360.	2.2	13
43	Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database. <i>Clinical and Experimental Neuroimmunology</i> , 2017, 8, 318-326.	1.0	20
44	The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. <i>Trends in Genetics</i> , 2017, 33, 960-970.	6.7	165
45	Five-Year Safety Data for More than 55,000 Subjects following Breast Implantation: Comparison of Rare Adverse Event Rates with Silicone Implants versus National Norms and Saline Implants. <i>Plastic and Reconstructive Surgery</i> , 2017, 140, 666-679.	1.4	46
46	MS in self-identified Hispanic/Latino individuals living in the US. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731772510.	1.0	9
47	Multiple Sclerosis in Latin Americans: Genetic Aspects. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 57.	4.2	14
48	Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis. <i>Journal of Medical Economics</i> , 2017, 20, 228-238.	2.1	17
49	An Evidence Map of the Women Veteransâ€™ Health Research Literature (2008â€“2015). <i>Journal of General Internal Medicine</i> , 2017, 32, 1359-1376.	2.6	60
50	Multiple Sclerosis; <i>Epidemiology & Health</i> , 2017, , ,		1
51	Multiple Sclerosis Mortality by Race/Ethnicity, Age, Sex, and Time Period in the United States, 1999â€“2015. <i>Neuroepidemiology</i> , 2018, 50, 35-40.	2.3	36
52	Lower prevalence of multiple sclerosis in First Nations Canadians. <i>Neurology: Clinical Practice</i> , 2018, 8, 33-39.	1.6	6
53	Temporal trends in multiple sclerosis prevalence and incidence in a large population. <i>Neurology</i> , 2018, 90, e1435-e1441.	1.1	60
54	Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate. <i>Current Medical Research and Opinion</i> , 2018, 34, 107-115.	1.9	14
55	The Gulf War era multiple sclerosis cohort: 3. Early clinical features. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 76-84.	2.1	6

#	ARTICLE	IF	CITATIONS
56	Ethnic Considerations and Multiple Sclerosis Disease Variability in the United States. <i>Neurologic Clinics</i> , 2018, 36, 151-162.	1.8	36
57	Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1362-1371.	3.7	20
58	Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence. <i>Psychopharmacology</i> , 2018, 235, 3303-3313.	3.1	17
59	Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study. <i>Brain</i> , 2018, 141, 3115-3129.	7.6	67
60	Signaling pathways and therapeutic perspectives related to environmental factors associated with multiple sclerosis. <i>Journal of Neuroscience Research</i> , 2018, 96, 1831-1846.	2.9	8
61	Salivary biomarkers for the diagnosis and monitoring of neurological diseases. <i>Biomedical Journal</i> , 2018, 41, 63-87.	3.1	122
62	Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. <i>Pharmacoeconomics</i> , 2018, 36, 1223-1252.	3.3	16
63	Hypothesis: Multiple sclerosis is caused by three-hits, strictly in order, in genetically susceptible persons. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 157-174.	2.0	12
64	MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics. <i>Nutrients</i> , 2018, 10, 268.	4.1	58
65	Association between Allelic Variants of IL2, IL2RA, and IL7R Genes and Multiple Sclerosis. <i>Russian Journal of Genetics</i> , 2019, 55, 487-494.	0.6	4
66	Cord-“Age-“Gender Connections Shape the Pathophysiology of Multiple Sclerosis Progressive Forms. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5103.	4.1	2
67	Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2019, 18, 983-985.	10.2	1
68	Unmasking the Masquerader: A Delayed Diagnosis of MS and Its 4.5% Years of Implications in an Older African American Male. <i>Case Reports in Medicine</i> , 2019, 2019, 1-5.	0.7	2
69	Unraveling susceptibility to multiple sclerosis. <i>Science</i> , 2019, 365, 1383-1384.	12.6	7
70	Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 269-285.	10.2	716
71	Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan. <i>Frontiers in Endocrinology</i> , 2019, 10, 265.	3.5	111
72	A novel comprehensive paradigm for the etiopathogenesis of multiple sclerosis: therapeutic approaches and future perspectives on its treatment. <i>Amino Acids</i> , 2019, 51, 745-759.	2.7	17
73	The prevalence of MS in the United States. <i>Neurology</i> , 2019, 92, e1029-e1040.	1.1	765

#	ARTICLE	IF	CITATIONS
74	Validation of an algorithm for identifying MS cases in administrative health claims datasets. <i>Neurology</i> , 2019, 92, e1016-e1028.	1.1	69
75	Epstein-Barr Virus in Multiple Sclerosis. , 2019, , .		1
76	Comment on “US FDA Breast Implant Postapproval Studies: Long-term Outcomes in 99,993 Patients” <i>Annals of Surgery</i> , 2019, 270, e55-e57.	4.2	3
77	US FDA Breast Implant Postapproval Studies. <i>Annals of Surgery</i> , 2019, 269, 30-36.	4.2	205
78	The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1329-1339.	3.0	23
79	Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1948-1952.	3.0	25
80	Siponimod and CYP2C9 Allele Prevalence Among Blacks. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 429-431.	2.0	5
81	Comparative United States autoimmune disease rates for 2010–2016 by sex, geographic region, and race. <i>Autoimmunity Reviews</i> , 2020, 19, 102423.	5.8	68
82	Two genetic variants explain the association of European ancestry with multiple sclerosis risk in African-Americans. <i>Scientific Reports</i> , 2020, 10, 16902.	3.3	10
83	Feasibility of “Sit Less, Move More”: An intervention for reducing sedentary behavior Among African Americans with MS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732093234.	1.0	4
84	Multiple Sclerosis in a Multi-Ethnic Population in Houston, Texas: A Retrospective Analysis. <i>Biomedicine</i> , 2020, 8, 534.	3.2	7
85	Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2020, 30, 342-350.	2.0	12
86	Psycho-neuro-endocrino-immunologic issues in multiple sclerosis: a critical review of clinical and therapeutic implications. <i>Hormones</i> , 2020, 19, 485-496.	1.9	12
87	CD8 T-cell Recruitment Into the Central Nervous System of Cuprizone-Fed Mice: Relevance to Modeling the Etiology of Multiple Sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 43.	3.7	22
88	Natural killer cells in multiple sclerosis: A review. <i>Immunology Letters</i> , 2020, 222, 1-11.	2.5	34
89	Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101959.	2.0	20
90	Race and ethnicity on MS presentation and disease course. <i>Multiple Sclerosis Journal</i> , 2020, 26, 561-567.	3.0	78
91	Physical activity and peak oxygen consumption are associated with walking in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101941.	2.0	5

#	ARTICLE	IF	CITATIONS
92	Prevalence and incidence of multiple sclerosis in Ardabil, Northwest of Iran. Multiple Sclerosis and Related Disorders, 2021, 47, 102605.	2.0	6
93	Epidemiology of Multiple Sclerosis and Environmental Risk Factors. , 2021, , 137-153.		0
95	Perceptions and Preferences Regarding Multiple Sclerosis Research Among Racial and Ethnic Groups. International Journal of MS Care, 2021, 23, 170-177.	1.0	15
96	Progress in progestin-based therapies for neurological disorders. Neuroscience and Biobehavioral Reviews, 2021, 122, 38-65.	6.1	20
97	Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review. Frontiers in Neurology, 2021, 12, 554375.	2.4	18
98	How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity. Neurology: Clinical Practice, 2021, 11, 335-341.	1.6	25
99	Ethnicity and multiple sclerosis - moving beyond preconceptions. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 0, 20, .	0.1	2
100	Liver kinase B1 rs9282860 polymorphism and risk for multiple sclerosis in White and Black Americans. Multiple Sclerosis and Related Disorders, 2021, 55, 103185.	2.0	3
101	Prognostic factors of disability in relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 30, 9-16.	2.0	52
102	Racial and Ethnic Differences in Individuals with Sporadic Creutzfeldt-Jakob Disease in the United States of America. PLoS ONE, 2012, 7, e38884.	2.5	7
103	Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT. Health Technology Assessment, 2020, 24, 1-182.	2.8	14
104	Muscle Dysfunction and Walking Impairment in Women with Multiple Sclerosis. International Journal of MS Care, 2019, 21, 249-256.	1.0	14
105	Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis. Biomolecules, 2021, 11, 1510.	4.0	19
106	Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US. JAMA Neurology, 2021, 78, 1515.	9.0	68
107	What Could Be a Primary Cause of Multiple Sclerosis: Is It an Autoimmunity Triggered by Chronic Protozoan Infection?. Journal of Neuroparasitology, 2013, 4, 1-10.	0.6	1
108	Multiple Sclerosis; Epidemiology. , 2014, , 153-160.		0
109	Preliminary Study of Differences Between Prevalence of Multiple Sclerosis in Isfahan and itsâ€™ Rural Provinces. Archives of Neuroscience, 2015, 2, .	0.3	2
110	Epidemiology and Genetics. Current Clinical Neurology, 2020, , 71-87.	0.2	1

#	ARTICLE	IF	CITATIONS
111	Comparing the Workplace Discrimination Experiences of Older and Younger Workers With Multiple Sclerosis Under the Americans With Disabilities Act Amendments Act. Journal of Applied Rehabilitation Counseling, 2020, 51, 168-179.	0.2	0
112	Differences in Cardiometabolic Comorbidities Between Black and White Persons Living With Multiple Sclerosis. Archives of Physical Medicine and Rehabilitation, 2022, 103, 331-335.	0.9	1
113	The Evaluation of Multiple Sclerosis Dispersal in Iran and Its Association with Urbanization, Life Style and Industry. Iranian Journal of Public Health, 2015, 44, 830-8.	0.5	22
114	Multidisciplinary Management of a Patient With Multiple Sclerosis: Part 1. Neurologists' and Psychiatrists' Perspectives. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 14S-17S.	0.6	0
115	The Multiple Sclerosis Surveillance Registry: A Novel Interactive Database Within the Veterans Health Administration. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2020, 37, S18-S23.	0.6	2
116	Non-White Participants Matter in White Matter Disease Studies. Neurology, 2022, 98, 345-346.	1.1	4
117	Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs. Neurology, 2022, 98, .	1.1	28
118	Quality of Life in Multiple Sclerosis Patients: Influence of Gender, Age and Marital Status. Materia Socio-medica, 2022, 34, 19.	0.7	8
119	MS Trials Continue to Under-Report, Under-Represent Non-White Participants. Neurology Today: an Official Publication of the American Academy of Neurology, 2022, 22, 12-13.	0.0	0
120	The impact of post-traumatic stress on quality of life and fatigue in women with Gulf War Illness. BMC Psychology, 2022, 10, 42.	2.1	5
121	Association of pregnancies with risk of multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 1630-1640.	3.0	2
122	Factors associated with requesting accommodations among people with multiple sclerosis. Work, 2022, 71, 1051-1061.	1.1	1
123	A Systematic Review of Tissue and Single Cell Transcriptome/Proteome Studies of the Brain in Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 761225.	4.8	6
124	The role of sex and pregnancy in multiple sclerosis: what do we know and what should we do?. Expert Review of Neurotherapeutics, 2022, 22, 377-392.	2.8	2
126	Prevalence of multiple sclerosis and treatment utilization in a large, highly diverse population. Multiple Sclerosis and Related Disorders, 2022, 61, 103784.	2.0	1
127	The Impact of <i>CYP2C9*11</i> Allelic Variant on the Pharmacokinetics of Phenytoin and <i>S</i> -Warfarin. Clinical Pharmacology and Therapeutics, 2022, 112, 156-163.	4.7	5
128	Multiple Sclerosis Incidence in Black Patients. Neurology, 2022, 98, 739-740.	1.1	2
129	Racial and Ethnic Disparities in Multiple Sclerosis Prevalence. Neurology, 2022, 98, .	1.1	48

#	ARTICLE	IF	CITATIONS
130	Variation of genes encoding nitric oxide synthases and antioxidant enzymes as potential risks of multiple sclerosis development: a preliminary study. Scientific Reports, 2022, 12, .	3.3	5
131	Optic neuritis: A South African hospital-based prospective study protocol. PLoS ONE, 2022, 17, e0269514.	2.5	0
132	FutureMS cohort profile: a Scottish multicentre inception cohort study of relapsing-remitting multiple sclerosis. BMJ Open, 2022, 12, e058506.	1.9	5
133	Burden of neurological disease. , 2023, , 1047-1064.		0
134	Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon Î²-1a phase 1 study. Med, 2022, , .	4.4	0
135	Genetics of multiple sclerosis: lessons from polygenicity. Lancet Neurology, The, 2022, 21, 830-842.	10.2	26
136	Towards a global view of multiple sclerosis genetics. Nature Reviews Neurology, 2022, 18, 613-623.	10.1	9
137	Pathogenesis and management of multiple sclerosis revisited. Disease-a-Month, 2023, 69, 101497.	1.1	3
138	Social determinants of health in multiple sclerosis. Nature Reviews Neurology, 2022, 18, 723-734.	10.1	28
139	Examination of Ligand-Receptor Interactions amongst Different Multiple Sclerosis Lesion Types. SunText Review of Neuroscience & Psychology, 2022, 03, .	0.1	0
140	An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis. Cureus, 2023, , .	0.5	4
141	Differential DNA methylation associated with multiple sclerosis and disease modifying treatments in an underrepresented minority population. Frontiers in Genetics, 0, 13, .	2.3	1
142	Neuroimmunological Disorders. Neurologic Clinics, 2023, 41, 315-330.	1.8	2
143	Epsteinâ€Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nature Reviews Neurology, 2023, 19, 160-171.	10.1	48
144	Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies. Frontiers in Neurology, 0, 14, .	2.4	1
146	Global, regional, and national burden of multiple sclerosis from 1990 to 2019: Findings of global burden of disease study 2019. Frontiers in Public Health, 0, 11, .	2.7	8
147	The Pathological Activation of Microglia Is Modulated by Sexually Dimorphic Pathways. International Journal of Molecular Sciences, 2023, 24, 4739.	4.1	2
148	Multiple sclerosis in Indigenous Peoples of the Americas: A systematic review of incidence, prevalence, and outcomes. Multiple Sclerosis and Related Disorders, 2023, 72, 104612.	2.0	1

#	ARTICLE	IF	CITATIONS
149	A case-control study of drinking beverages and the risk of multiple sclerosis in Iran. <i>Journal of Health, Population and Nutrition</i> , 2023, 42, .	2.0	1
150	Health Disparities in Multiple Sclerosis among Hispanic and Black Populations in the United States. <i>Biomedicine</i> , 2023, 11, 1227.	3.2	2
152	Ultrasound measures of muscle morphology in people with multiple sclerosis are associated with muscle performance and functional mobility. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 75, 104759.	2.0	1
153	The impact of menopause on multiple sclerosis. <i>Autoimmunity Reviews</i> , 2023, 22, 103363.	5.8	1
154	Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 76, 104794.	2.0	1
155	Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	6
156	Racial and Ethnic Differences in the Severity of Sexual Dysfunction Symptoms in Patients with Multiple Sclerosis. <i>Sexuality and Disability</i> , 2023, 41, 543-554.	1.0	0
157	Making Sure Multiple Sclerosis Counts and Is Counted for All—An Update on Multiple Sclerosis Prevalence by Race and Ethnicity in the United States. <i>JAMA Neurology</i> , 2023, 80, 667.	9.0	0
158	Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. <i>JAMA Neurology</i> , 2023, 80, 693.	9.0	15
159	Impact of the first Gulf war on multiple sclerosis risk in Kuwait: a quasi-experimental study. <i>BMC Neurology</i> , 2023, 23, .	1.8	1
160	Social determinants of health and disparate disability accumulation in a cohort of Black, Hispanic, and White patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2023, 29, 1304-1315.	3.0	2
161	Multiple Sclerosis in Black and Hispanic Populations. <i>Neurologic Clinics</i> , 2023, , .	1.8	0
162	Vitamin D and the epidemiology of multiple sclerosis. , 2024, , 1167-1184.		0
163	Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2024, 81, 105153.	2.0	1
164	Smoking and multiple sclerosis risk in black people: A nested case-control study. <i>Multiple Sclerosis and Related Disorders</i> , 2024, 81, 105375.	2.0	0
165	MULTIPLE SCLEROSIS: AN EMERGENCY MEDICINE-FOCUSED NARRATIVE REVIEW. <i>Journal of Emergency Medicine</i> , 2023, , .	0.7	0
166	Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies. <i>Neurology</i> , 2024, 102, .	1.1	0